Pages that link to "Q71854843"
Jump to navigation
Jump to search
The following pages link to A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia (Q71854843):
Displaying 34 items.
- Antidepressants for the negative symptoms of schizophrenia (Q24245099) (← links)
- Augmentation with antidepressants in schizophrenia treatment: benefit or risk (Q26851841) (← links)
- Randomized Controlled Trials of Add-On Antidepressants in Schizophrenia (Q28080437) (← links)
- Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis (Q28292187) (← links)
- Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors (Q28299615) (← links)
- Co-prescription of cytochrome P450 2D6/3A4 inhibitor-substrate pairs in clinical practice. A retrospective analysis of data from Norwegian primary pharmacies. (Q30982105) (← links)
- The effect of selective serotonin reuptake inhibitors (SSRIs) on the pharmacokinetics and metabolism of perazine in the rat. (Q33181987) (← links)
- Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors (Q33668203) (← links)
- Pharmacokinetics of haloperidol: an update (Q33813315) (← links)
- The antipsychotic drug risperidone interacts with auto- and hetero-receptors regulating serotonin output in the rat frontal cortex (Q33872125) (← links)
- Fluvoxamine as an adjunctive agent in schizophrenia (Q34405313) (← links)
- Managing suicide risk in patients with schizophrenia (Q34664040) (← links)
- Antidepressants for people with both schizophrenia and depression (Q34699114) (← links)
- Co-occurring depressive symptoms in the older patient with schizophrenia (Q35008098) (← links)
- Management of the negative symptoms of schizophrenia: new treatment options (Q35201017) (← links)
- Selective serotonin reuptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia (Q35565079) (← links)
- Evidence-based treatment for schizophrenia (Q35623212) (← links)
- Pharmacokinetic factors in the adverse cardiovascular effects of antipsychotic drugs (Q35625348) (← links)
- Future perspectives on the treatment of cognitive deficits and negative symptoms in schizophrenia (Q36930839) (← links)
- Synergetic effects of quetiapine and venlafaxine in preventing the chronic restraint stress-induced decrease in cell proliferation and BDNF expression in rat hippocampus (Q40328948) (← links)
- Drug treatment of schizophrenia in the 1990s. Achievements and future possibilities in optimising outcomes (Q40893820) (← links)
- Clinically significant interactions of psychotropic agents with antipsychotic drugs (Q41241532) (← links)
- Risperidone inhibits 5‐hydroxytryptaminergic neuronal activity in the dorsal raphe nucleus by local release of 5‐hydroxytryptamine (Q41766333) (← links)
- Differential effects of chronic imipramine and fluoxetine on basal and amphetamine-induced extracellular dopamine levels in rat nucleus accumbens (Q42486380) (← links)
- More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: an extension phase of a randomized controlled trial (Q42673319) (← links)
- Citalopram augmentation of antipsychotic treatment in older schizophrenia patients (Q43827152) (← links)
- SLV310, a novel, potential antipsychotic, combining potent dopamine D2 receptor antagonism with serotonin reuptake inhibition (Q44301630) (← links)
- Fluoxetine Augmentation of Haloperidol in Chronic Schizophrenia (Q44603300) (← links)
- Dopamine and serotonin metabolism in response to chronic administration of fluvoxamine and haloperidol combined treatment (Q48132556) (← links)
- The involvement of GABA(A) receptor in the molecular mechanisms of combined selective serotonin reuptake inhibitor-antipsychotic treatment (Q48295240) (← links)
- Modulation of central serotonergic neurotransmission by risperidone: underlying mechanism(s) and significance of action (Q48402858) (← links)
- Effects of diazepam, citalopram, methadone and naloxone on PCP-induced stereotyped behaviour and social isolation in the rat social interaction test (Q51481810) (← links)
- Sense and non-sense of polypharmacy: increasing efficacy, decreasing compliance? (Q52007491) (← links)
- Pharmacological treatment of negative symptoms in schizophrenia: update and proposal of a clinical algorithm. (Q64965194) (← links)